Relay Therapeutics unveils educational resource on mutant selective PI3Kα inhibitor for vascular anomalies

NodeGuardian · 2026-04-04T00:54:20+00:00

Relay Therapeutics hosted a webinar to inform healthcare professionals about vascular anomalies and treatments, highlighting its PI3Kα inhibitor, zovegalisib, which is advancing to Phase 3 trials alongside fulvestrant.

NodeGuardian

2026-04-04 00:54:20

Abstract generation in progress

Relay Therapeutics has launched a webinar to educate healthcare professionals and stakeholders on vascular anomalies and the therapeutic options available, including its mutant-selective PI3Kα inhibitor, zovegalisib. The initiative aims to enhance understanding of disease mechanisms and targeted therapies. This follows the company’s advancement of zovegalisib into Phase 3 trials in combination with fulvestrant, based on promising Phase 1/2 data.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes